Effectiveness of a segmental thermo-expandable metal alloy spiral stent (Memokath 051TM) and self-expandable covered metallic stent (UVENTATM) in the

2323 Words5 Pages

Introduction Ureteral obstruction can be occurred by benign condition such as ureteral stricture, or malignant disease. It is important that decompression of the ureteral obstruction and preserving renal function. First reported of double-J stents as a treatment for ureteral obstruction in 1978[1], Up to recently, ureteral obstruction generally was managed by indwelling double J stents. Advantages of double J stents are easy to inserting and rapid relieving of obstruction. Despite of advantages, they have some adverse side effects. Early side effects are stent discomfort, irritative lower urinary symptoms, hematuria, bacteriuria, fever, flank pain. Late side effects are stent migration, encrustation, fragmentation, forgotten.[2, 3] Other important drawback of double J stents is high rates of failure in management of ureteral obstruction by extrinsic causes, such as advanced malignancy.[4, 5] hence, the use of double J stents in malignant ureteral obstruction is controversy. Other option of decompression of ureteral obstruction is percutaneous nephrostomy (PCN). Although PCN has high successful rate for decompression of the ureteral obstruction, low quality of life by the external tube with drainage bag and easy dislodgement makes urologist hesitate to keep PCN to patients. To remedy shortcoming of double J stents and PCN, various kinds of new stents have been developed; coiled metal wire stents, (Resonance, Cook Urological, Indiana, USA) metal coil-reinforced double J stents, (Silhouette, Applied Medical, Cleveland, USA) segmental thermo expandable metal alloy stents (Memokath 051, PNN Medical, Denmark) self-expandable covered metallic stents (UVENTA, Taewoong Medical, Korea), and so on. To our knowledge this study represents the... ... middle of paper ... ...t al., Use of a segmental thermoexpandable metal alloy stent in the management of malignant ureteric obstruction: a single centre experience in the UK. Urol Int, 2011. 87(4): p. 405-10. 12. Barbalias, G.A., et al., Externally coated ureteral metallic stents: an unfavorable clinical experience. Eur Urol, 2002. 42(3): p. 276-80. 13. Siddique, K.A., et al., Repositioning and removal of an intra-renal migrated ureteric Memokath stent. Urol Int, 2006. 77(4): p. 297-300. 14. Chung, K.J., et al., Efficacy and safety of a novel, double-layered, coated, self-expandable metallic mesh stent (Uventa) in malignant ureteral obstructions. J Endourol, 2013. 27(7): p. 930-5. 15. Kim, J.H., et al., Palliative care of malignant ureteral obstruction with polytetrafluoroethylene membrane-covered self-expandable metallic stents: initial experience. Korean J Urol, 2012. 53(9): p. 625-31.

More about Effectiveness of a segmental thermo-expandable metal alloy spiral stent (Memokath 051TM) and self-expandable covered metallic stent (UVENTATM) in the

Open Document